# A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

> clinical trial · VERIFIED · 2026-07-13

Status: RECRUITING · Sponsor: AstraZeneca · Condition: Multiple Myeloma

- Company: AstraZeneca
- Sector: Multiple Myeloma
- Primary source: https://clinicaltrials.gov/study/NCT07073547

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.